Abstract:Summary Background With the increasing use of immune checkpoint inhibitors (ICIs) for tumour immunotherapy, the immune-related adverse events (irAEs) caused by their collateral effect on the immune system pose a key challenge for the clinical application of ICIs. Psychiatric adverse events are a class of adverse events associated with ICIs that are realistically observed in the real world. We aim to provide a comprehensive study and summary of psychiatric adverse events associated with ICIs. Methods We obtained ICI adverse reaction reports during January 2012–December 2021 from the FDA Adverse Event Reporting System (FAERS) database. ICI reports underwent screening to minimize the influence of other adverse reactions, concomitant medications, and indications for medication use that may also contribute to psychiatric disorders. Disproportionality analysis was performed to find psychiatric adverse events associated with ICIs by comparing ICIs with the full FAERS database using the reporting odds ratio (ROR). Influencing factors were explored based on univariate logistic regression analysis. Finally, the Cancer Genome Atlas (TCGA) pan-cancer transcriptome data were combined to explore the potential biological mechanisms associated with ICI-related pAEs. Findings Reports of psychiatric adverse events accounted for 2.71% of the overall ICI adverse event reports in the FAERS database. Five categories of psychiatric adverse events were defined as ICI-related psychiatric adverse events (pAEs). The median age of reports with ICI-related pAEs was 70 (interquartile range [IQR] 24–95), with 21.54% of reports having a fatal outcome. Cases with indications for lung cancer, skin cancer and kidney site cancer accounted for the majority. The odds of ICI-related pAEs increased in older patients (65–74: OR = 1.44 [1.22–1.70], P < 0.0001: ≥75: OR = 1.84 [1.54–2.20], P < 0.0001). The occurrence of ICI-related pAEs may be related to NOTCH signalling and dysregulation of synapse-associated pathways. Interpretation This study investigated psychiatric adverse events highly associated with ICI treatment, their influencing factors and potential biological mechanisms, which provides a reliable basis for further in-depth study of ICI-related pAEs. However, as an exploratory study, our findings need to be further confirmed in a large-scale prospective study. Funding This work was supported by the Natural Science Foundation of Guangdong Province ( 2018A030313846 and 2021A1515012593 ), the Science and Technology Planning Project of Guangdong Province ( 2019A030317020 ) and the National Natural Science Foundation of China ( 81802257 , 81871859 , 81772457 , 82172750 and 82172811 ). Guangdong Basic and Applied Basic Research Foundation ( Guangdong - Guangzhou Joint Fouds ) ( 2022A1515111212 ). This work was supported by Key Research and Development Projects of Sichuan Science and Technology ( 2022YFS0221 , 2022YFS0074 , 2022YFS0156 and 2022YFS0378 ). Sichuan Provincial People's Hospital Hospital Young Talent Fund ( 2021QN08 ).

Immune-related Interstitial Lung Disease Induced by Different Immune Checkpoint Inhibitors Regimens: A Real-World Study from 2014 to 2022 Based on FAERS Databases.

Immune-related interstitial lung disease adverse event following immune checkpoint inhibitors and immune checkpoint inhibitors plus anti-VEGF antibody/chemotherapy: A real-world study from 2014 to 2022 based on FAERS databases

Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022)

Renal Adverse Effects Following The Use Of Different Immune Checkpoint Inhibitor Regimens: A Real-World Pharmacoepidemiology Study Of Post-Marketing Surveillance Data

Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non–small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system

Toxicity Spectrum of Immunotherapy in Advanced Lung Cancer: A Safety Analysis from Clinical Trials and a Pharmacovigilance System.

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System

1071P Analysis of Pulmonary Adverse Events Associated with Immune Checkpoint Inhibitors Based on FAERS and VigiBase Database

Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis

Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system

Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China

Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database

Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System

Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022

Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database

Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system

Analysis of the association between immune-related adverse events and the effectiveness in patients with advanced non-small-cell-lung cancer

Adverse events in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A single center, real-world study in China.